Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

NCT05484206 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment
Cirrhosis

Interventions

DRUG: VIR-2218
DRUG: VIR-3434

Sponsor

Vir Biotechnology, Inc.